Emphysema clinical trials at University of California Health

5 in progress, 2 open to eligible people

Showing trials for

  • Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

    open to eligible people ages 30 years and up

    The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.

    at UCLA UCSD

  • INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

    open to eligible people ages 18-80

    Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema

    at UC Davis UCLA

  • Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

    Sorry, in progress, not accepting new patients

    Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is often caused by cigarette smoking. The purpose of this study is to evaluate whether certain genetic factors predispose some smokers to develop COPD more than others.

    at UCSD

  • Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

    Sorry, accepting new patients by invitation only

    The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as retrospective standard of care patients

    at UCSF

  • COPD Subgroups and Biomarkers

    Sorry, in progress, not accepting new patients

    SPIROMICS I and SPIROMICS II are observational studies of Chronic Obstructive Pulmonary Disease (COPD). SPIROMICS I had two main aims: (1) To find groups of patients with COPD who share certain characteristics; (2) To find new ways of measuring whether or not COPD is getting worse and so provide new ways of testing whether a new treatment is working. SPIROMICS II has three primary aims. Aim 1 is to define the natural history of "Smokers with symptoms despite preserved spirometry" and characterize the airway mucus abnormalities underlying this condition. Aim 2 is to determine the radiographic precursor lesion(s) for emphysema, and identify the molecular phenotypes underlying airway disease and emphysema. Aim 3 is to advance understanding of the biology of COPD exacerbations through analysis of predisposing baseline phenotypes, exacerbation triggers and host inflammatory response.

    at UCLA UCSF

Our lead scientists for Emphysema research studies include .

Last updated: